Effects of Sarcopenia, Myosteatosis, and the Prognostic Nutritional Index on Survival in Stage 2 and 3 Gastric Cancer Patients. (13th December 2022)

• Record Type: Journal Article
• Authors: Bir Yucel, Kadriye; Karabork Kilic, Atiye Cenay; Sutcuoglu, Osman; Yazıcı, Ozan; Aydos, Uguray; Kilic, Koray; Özdemir, Nuriye
• Is Part Of: Nutrition and cancer. Volume 75:Number 1(2023)
• Page Start: 368
• Page End: 375
• Publication Date: 2022-12-13
• Subjects: Cancer -- Periodicals; Nutrition -- Periodicals; Cancer; Nutrition; Periodicals; 616.9940654
• DOI: 10.1080/01635581.2022.2121845
• Languages: English
• ISSNs: 0163-5581

Abstract

Abstract: Background: We aimed to evaluate the relationship between sarcopenia, myosteatosis, and systemic inflammatory response biomarkers and their prognostic role in stage 2 and 3 gastric cancer patients. Methods: This study included 84 patients with stage 2 or 3 gastric cancer who underwent a gastrectomy. Computed tomography scans were used to determine the skeletal muscle index (SMI) at the third lumbar vertebra level for sarcopenia and myosteatosis. Results: Based on the Asian Working Group of Sarcopenia (AWGS2019) criteria, the sarcopenia incidence was 36.9% and that of myosteatosis 46.4%. Univariate analysis showed that sarcopenia (48 vs. 14 mo, p < 0.001), myosteatosis (45 vs. 16 mo, p = 0.016), a low prognostic nutritional index (60 vs. 15 mo, p = 0.003), stage 3 (104 vs. 21 mo, p = 0.013), and old age (45 vs. 16 mo, p = 0.015) were poor prognostic markers. Multivariate analysis revealed that sarcopenia (AWGS2019), age, and stage significantly affected overall survival (hazard ratio: 3.31, 95% CI: 1.85–5.1; 1.96, 95% CI: 1.06–6.63; 2.5, 95% CI: 1.2–5.1, respectively). Conclusion: We showed that sarcopenia directly affects overall gastric cancer survival.